<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02903251</url>
  </required_header>
  <id_info>
    <org_study_id>140682</org_study_id>
    <secondary_id>2015-004463-37</secondary_id>
    <nct_id>NCT02903251</nct_id>
  </id_info>
  <brief_title>Oxytocin and Alcohol Withdrawal and Dependence</brief_title>
  <official_title>Acute and Long-term Effects of Intranasal Oxytocin in Alcohol Withdrawal and Dependence: A Prospective Randomized Parallel Group Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lade Addiction Treatment Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of oxytocin nasal spray on alcohol withdrawal and dependence
      in adults admitted for detoxification of alcohol, and during the following 4 weeks in an
      outpatient setting. Half of the participants will receive oxytocin nasal spray, the other
      half placebo nasal spray.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">January 22, 2018</completion_date>
  <primary_completion_date type="Actual">January 22, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total oxazepam dosage in milligrams</measure>
    <time_frame>3 days</time_frame>
    <description>total oxazepam dosage per subject during detoxification, as determined by Clinical Institute Withdrawal Assessment-Alcohol, Revised (CIWA-Ar) scores</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alcohol intake</measure>
    <time_frame>30 days</time_frame>
    <description>Alcohol intake of outpatients, using blood, urine, Timeline Followback and diaries.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>3 days</time_frame>
    <description>self-reported sleeping hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>30 days</time_frame>
    <description>self-reported sleeping hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>motor activity</measure>
    <time_frame>3 days</time_frame>
    <description>assessed by actigraph</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alcohol craving</measure>
    <time_frame>day 3</time_frame>
    <description>self-reported using Alcohol Craving questionnaire short form revised, Norwegian version (ACQ-SF-R)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alcohol craving</measure>
    <time_frame>day 30</time_frame>
    <description>self-reported using Alcohol Craving questionnaire short form revised, Norwegian version (ACQ-SF-R)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental distress</measure>
    <time_frame>day 3</time_frame>
    <description>measured by Hopkins Symptoms Checklist 10 items (SCL-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental distress</measure>
    <time_frame>day 30</time_frame>
    <description>measured by Hopkins Symptoms Checklist 10 items (SCL-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient activity</measure>
    <time_frame>day 3</time_frame>
    <description>measured by Patient Activity Measure 13 (PAM-13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient activity</measure>
    <time_frame>day 30</time_frame>
    <description>measured by Patient Activity Measure 13 (PAM-13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Socio-emotional recognition</measure>
    <time_frame>Day 2</time_frame>
    <description>assessed by Reading the mind in the eyes test (RMET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Socio-emotional recognition</measure>
    <time_frame>Day 3</time_frame>
    <description>assessed by Reading the mind in the eyes test (RMET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Socio-emotional recognition</measure>
    <time_frame>day 30</time_frame>
    <description>assessed by Reading the mind in the eyes test (RMET)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial emotional selective attention</measure>
    <time_frame>Day 2</time_frame>
    <description>assessed by Visual Dot probe task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial emotional selective attention</measure>
    <time_frame>Day 3</time_frame>
    <description>assessed by Visual Dot probe task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial emotional selective attention</measure>
    <time_frame>day 30</time_frame>
    <description>assessed by Visual Dot probe task</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Alcoholism</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.
Day 3-30: Self-administered intranasal spray as needed, max thrice daily intranasal spray without oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.
Day 3-30: Self-administered intranasal spray as needed, max thrice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal oxytocin spray</intervention_name>
    <description>6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30.</description>
    <arm_group_label>oxytocin</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intranasal spray without oxytocin</intervention_name>
    <description>6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least one prior episode 2 days or longer in duration during which the subject
             experienced withdrawal symptoms that caused significant incapacitation (e.g.,
             inability to work or do normal activities) OR at least one prior inpatient or
             outpatient medical detoxification during which the subject exhibited withdrawal
             symptoms of sufficient magnitude that sedative-hypnotic or anticonvulsant medication
             was required at least once on 2 consecutive days after cessation of or reduction in
             the use of alcohol following 2 weeks or more of heavy daily consumption

          2. average consumption of 8-30 standard drinks per day for at least 2 weeks prior to
             enrollment in the study;

          3. consenting to participate in the study;

          4. have residency in Tr√∏ndelag County after discharge

        Exclusion Criteria:

          1. chronic treatment with sedative-hypnotic medications such as benzodiazepines or
             z-hypnotics;

          2. dependence on substances other than alcohol, nicotine or caffeine;

          3. inadequately treated, unstable and/or compromising medical or psychiatric conditions;

          4. low body weight (BMI &lt; 17) or history of anorexia nervosa or bulimia in the past 2
             years;

          5. pregnancy; parturition or breast-feeding in the past 6 months;

          6. inability to read well enough to complete study questionnaires determined by whether
             the prospective subject can read the consent form without help and correctly answer
             basic questions about information in the consent form;

          7. no alcohol in the blood and &gt; 15 h since last intake of alcohol;

          8. prior inclusion and participation in the same study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trond Jacobsen, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>St Olav's University Hospital Trondheim</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olav Spigset, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lade Addiction Treatment Center</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxytocin</keyword>
  <keyword>Administration, Intranasal</keyword>
  <keyword>Ethanol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

